TaiMed Biologics Capital Reinvestment Ratio

Latest as of June 2026: 0.45x

TaiMed Biologics capital reinvestment ratio. TaiMed Biologics (4147) has a Capital Reinvestment Ratio of 0.45x as of June 2026, meaning it reinvests 0% of its operating cash flow (NT$58.88 Million) in capital expenditures (NT$26.35 Million). See TaiMed Biologics free cash flow ratio to measure how efficiently the company converts operating cash flow to free cash.

Capital Reinvestment Ratio

0.45x

Capex / Operating Cash Flow

Operating Cash Flow

NT$58.88 Million

TWD

Capital Expenditures

NT$26.35 Million

TWD

Data as of

Jun 2026

Most recent filing

Capital Reinvestment Ratio of TaiMed Biologics (2025–2025)

Capital reinvestment ratio of TaiMed Biologics from 2025 to 2025. This chart tracks TaiMed Biologics's Capital Reinvestment Ratio across 1 annual periods. See TaiMed Biologics (4147) flexibility index to measure the company's free cash flow as a share of total liabilities.

TaiMed Biologics Capital Reinvestment Ratio by Year (2025–2025)

TaiMed Biologics capital reinvestment ratio by year from 2025 to 2025. For the full cash flow conversion analysis, see 4147 cash generation efficiency.

Year	Reinvestment Ratio	Operating CF (TWD)	Capital Expenditures	YoY Change
2025	0.12x	NT$191.14 Million	NT$22.77 Million	—

Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow